

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**NOVARTIS CORP**

2. Address:

701 PENNSYLVANIA AVE NW #725, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: ANDREA MCCABE

Telephone: 202-638-7429

E-mail (optional): andrea.mccabe@group.novartis.com

Senate ID #: 9204-12

House ID #: 33589000

7. Client Name:  Self

## TYPE OF REPORT

8. Year 2002 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 1,498,110.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NOVARTIS CORP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S754/HR1063, Increasing Ability to Enforce Anti-trust laws S812/HR 1862, Greater Access to Affordable Pharmaceuticals Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CASSERLY, DAN

Covered Official Position (if applicable): N/A

Name: DRAKE, DAVID

Covered Official Position (if applicable): N/A

Name: ELKIN, JAMES R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the Degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: F00 (one per page)

16. Specific lobbying issues:

National Uniformity for Food Genetically Engineered Food Right to Know Act Country of Origin Labeling GMO Labeling

17. House(s) of Congress and Federal agencies contacted:

Agriculture, Dept of (USDA)  
Environmental Protection Agency (EPA)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DRAKE, DAVID  
Covered Official Position (if applicable): N/A  
Name: ELKIN, JAMES R.  
Covered Official Position (if applicable): N/A  
Name: HALLER, SARAH E.  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, wither laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

HR1387, Drug Availability and Health Care Access Improvement Act of 2001 HR1530, Prescription Drug Competition Act of 2001 HR1624/S913, Access to Cancer Therapies Act of 2001 S1239, Medicare Rx Drug Discount and Security Act of 2001 S10, Medicare Prescription Drug Coverage Act of 2001 S1135, Medicare Reform Act of 2001 S1185, Seniors Prescription Insurance Coverage Equity Act of 2001 S838, Better Pharmaceuticals for Children Act S880/HR1839, Immunosuppressive Drug Coverage Act of 2001 S982/HR2058, Medicare Wellness Act of 2001 Medicare Prescription Drugs Snow/Wyden The Senior Prescription Insurance Coverage Equity Act (S1185) Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Medical Records Privacy- Senators Jeffords, Bennett, Leahy, Kennedy Bills Prospective payment System Gene Therapy Drug Reimportation Medicare Reform Agriculture Appropriations 2001 - Drug Reimportation Agriculture Appropriation 2001 (FDA Funding) Stem Cell Research Pediatric Exclusivity Direct-to-Consumer Advertising PDUFA The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draft Bill) President Bush's "Helping Hand" proposal

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH

Covered Official Position (if applicable): N/A

Name: CASSERLY, DAN

Covered Official Position (if applicable): N/A

Name: DRAKE, DAVID

Covered Official Position (if applicable): N/A

Name: ELKIN, JAMES R.

Covered Official Position (if applicable): N/A

Name: HALLER, SARAH E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

HR1530, Prescription Drug Competition Act of 2001 HR1387, Drug Availability and Health Care Access Improvement Act of 2001 HR1624/S913, Access to Cancer Therapies Act S10, Medicare Prescription Drug Coverage Act of 2001 S1135, Medicare Reform Act 2001 S1185, Seniors Prescription Insurance Coverage Equity Act of 2001 S1239, Medicare Rx Drug Discount & Security Act of 2001 S880/HR1839, Immunosuppressive Drug Coverage Act of 2001 S982/S/HR2058/H, Medicare Wellness Act of 2001 Medicare Prescription Drug & Modernization Act The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draft Bill) President Bush's "Helping Hand" proposal Prospective payment system Medicare Reform Medicare Prescription Drug Benefit

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH  
Covered Official Position (if applicable): N/A  
Name: CASSERLY, DAN  
Covered Official Position (if applicable): N/A  
Name: DRAKE, DAVID  
Covered Official Position (if applicable): N/A  
Name: ELKIN, JAMES R.  
Covered Official Position (if applicable): N/A  
Name: HALLER, SARAH E.  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.  
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Economic Sanctions SRM Ban/BSE China/World Trade Organization Fast Track Negotiating Authority Capital Market Sanctions Chile and Singapore FTA's

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DRAKE, DAVID

Covered Official Position (if applicable): N/A

Name: HALLER, SARAH E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature: ON FILE Date: Aug 12, 2003

Printed Name and Title: DAN CASSELY - DIRECTOR, FEDERAL GOVERNMENT RELATIONS